Stockreport
3 Reasons to Sell REGN and 1 Stock to Buy Instead [Yahoo! Finance]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
This might have investors contemplating their next move. Is now the time to buy Regeneron, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team's opinion, it's free Despite the more favorable entry price, we don't have much confidence in Regeneron. Here are three reasons why you should be careful with REGN and a stock we'd rather own. Founded by scientists who wanted to build a company where science could thrive, Regeneron Pharmaceuticals (NASDAQ:REGN) develops and commercializes medicines for serious diseases, with key products treating eye conditions, allergic diseases, cancer, and other disorders. Forecasted revenues by Wall Street analysts signal a company's potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite. Over the next 12 months, sell-side analysts expect Regeneron's revenue to rise b
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Regeneron (REGN) Is Up 5.4% After New Myeloma Data And Gene Writing Tie-Up With Tessera [Yahoo! Finance][Yahoo! Finance]
- 2 Reasons to Buy Regeneron Stock Like There's No Tomorrow [Yahoo! Finance][Yahoo! Finance]
- Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an "equal weight" rating on the stock.[MarketBeat]
- Biohaven jumps on early-stage data for antibody drug conjugate combo [Seeking Alpha][Seeking Alpha]
- 3 Low-Volatility Stocks We're Skeptical Of [Yahoo! Finance][Yahoo! Finance]
- More
REGN
SEC Filings
SEC Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- REGN's page on the SEC website
- More